130 related articles for article (PubMed ID: 35770251)
1. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.
Khairullin B; Zakarya K; Orynbayev M; Abduraimov Y; Kassenov M; Sarsenbayeva G; Sultankulova K; Chervyakova O; Myrzakhmetova B; Nakhanov A; Nurpeisova A; Zhugunissov K; Assanzhanova N; Nurabayev S; Kerimbayev A; Yershebulov Z; Burashev Y; Kulmagambetov I; Davlyatshin T; Sergeeva M; Buzitskaya Z; Stukova M; Kutumbetov L
EClinicalMedicine; 2022 Aug; 50():101526. PubMed ID: 35770251
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.
Zakarya K; Kutumbetov L; Orynbayev M; Abduraimov Y; Sultankulova K; Kassenov M; Sarsenbayeva G; Kulmagambetov I; Davlyatshin T; Sergeeva M; Stukova M; Khairullin B
EClinicalMedicine; 2021 Sep; 39():101078. PubMed ID: 34414368
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
4. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
Al Kaabi N; Yang Y; Eldin Hussein S; Yang T; Abdalla J; Wang H; Lou Z; Chinese Center For Disease Control And Prevention ; Bakkour A; Arafat A; China National Biotec Group Company Limited ; Jiang Z; Tian Y; National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd ; Beijing Institute Of Biological Products Company Limited ; Xiao P; Zaher W; Eltantawy I; Wang C; Xu G; Zhang Y; Yang X
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851177
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
[TBL] [Abstract][Full Text] [Related]
13. A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Hernández-Bernal F; Ricardo-Cobas MC; Martín-Bauta Y; Rodríguez-Martínez E; Urrutia-Pérez K; Urrutia-Pérez K; Quintana-Guerra J; Navarro-Rodríguez Z; Piñera-Martínez M; Rodríguez-Reinoso JL; Chávez-Chong CO; Baladrón-Castrillo I; Melo-Suárez G; Batista-Izquierdo A; Pupo-Micó A; Mora-Betancourt R; Bizet-Almeida J; Martínez-Rodríguez MC; Lobaina-Lambert L; Velázquez-Pérez VM; Soler-Díaz J; Laurencio-Vallina S; Meriño-Hechavarría T; Carmenaty-Campos N; Rodríguez-Montero E; Limonta-Fernández M; Alonso-Valdés M; Hernández-Rodríguez R; Pimentel-Vázquez E; Catasús-Álvarez KM; Cabrera-Núñez MV; Ayala-Ávila M; Muzio-González VL;
Lancet Reg Health Am; 2023 May; 21():100497. PubMed ID: 37192953
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.
Nguyen TP; Do Q; Phan LT; Dinh DV; Khong H; Hoang LV; Nguyen TV; Pham HN; Chu MV; Nguyen TT; Pham QD; Le TM; Trang TNT; Dinh TT; Vo TV; Vu TT; Nguyen QBP; Phan VT; Nguyen LV; Nguyen GT; Tran PM; Nghiem TD; Tran TV; Nguyen TG; Tran TQ; Nguyen LT; Do AT; Nguyen DD; Ho SA; Nguyen VT; Pham DT; Tran HB; Vu ST; Hoang SX; Do TM; Nguyen XT; Le GQ; Tran T; Cao TM; Dao HM; Nguyen TTT; Doan UY; Le VTT; Tran LP; Nguyen NM; Nguyen NT; Pham HTT; Nguyen QH; Nguyen HT; Nguyen HLK; Tran VT; Tran MTN; Nguyen TTT; Ha PT; Huynh HT; Nguyen KD; Thuan UT; Doan CC; Do SM
Lancet Reg Health West Pac; 2022 Jul; 24():100474. PubMed ID: 35602004
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F; Ricardo-Cobas MC; Martín-Bauta Y; Navarro-Rodríguez Z; Piñera-Martínez M; Quintana-Guerra J; Urrutia-Pérez K; Urrutia-Pérez K; Chávez-Chong CO; Azor-Hernández JL; Rodríguez-Reinoso JL; Lobaina-Lambert L; Colina-Ávila E; Bizet-Almeida J; Rodríguez-Nuviola J; Del Valle-Piñera S; Ramírez-Domínguez M; Tablada-Ferreiro E; Alonso-Valdés M; Lemos-Pérez G; Guillén-Nieto GE; Palenzuela-Díaz A; Noa-Romero E; Limonta-Fernández M; Fernández-Ávila JM; Ali-Mros NA; Del Toro-Lahera L; Remedios-Reyes R; Ayala-Ávila M; Muzio-González VL
EClinicalMedicine; 2022 Apr; 46():101383. PubMed ID: 35434578
[TBL] [Abstract][Full Text] [Related]
20. Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial.
Yuki Y; Nojima M; Hosono O; Tanaka H; Kimura Y; Satoh T; Imoto S; Uematsu S; Kurokawa S; Kashima K; Mejima M; Nakahashi-Ouchida R; Uchida Y; Marui T; Yoshikawa N; Nagamura F; Fujihashi K; Kiyono H
Lancet Microbe; 2021 Sep; 2(9):e429-e440. PubMed ID: 35544149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
